Neomib 2 mg Injection
  1. Home
  2. Pharma Products
  3. Getwell oncology Pvt Ltd
  4. Neomib 2 mg Injection

Neomib 2 mg Injection

Neomib 2 mg Injection contains bortezomib 2 mg and is an anticancer medicine used in the treatment of multiple myeloma and mantle cell lymphoma. It is supplied as a single-dose vial and is administered by a healthcare professional through intravenous or subcutaneous injection according to the prescribed treatment protocol. Bortezomib works by inhibiting proteasomes, which can interfere with cancer-cell growth and survival.

BUY NOW

Category

Neomib belongs to the proteasome inhibitor class of anticancer medicines and is used in adults with multiple myeloma and mantle cell lymphoma in appropriate treatment settings. By blocking proteasome activity, bortezomib disrupts the normal processing of proteins within cancer cells and can promote their death. The medicine may be administered intravenously or subcutaneously, while the dose and treatment schedule are determined by the treating oncology team. Treatment requires monitoring for effects such as peripheral neuropathy, thrombocytopenia, neutropenia, gastrointestinal symptoms, and fatigue.

Technical Specification

Specification Details
Active Ingredient Bortezomib
Strength 2 mg
Dosage Form Injection
Presentation Single-dose vial
Route of Administration Intravenous or subcutaneous
Manufacturer Getwell Oncology Pvt Ltd

Product Also Known As

Neomib 2mg Injection, Neomib 2mg Vial, Bortezomib 2mg Injection, Bortezomib 2mg Vial, Bortezomib Injection 2mg, Bortezomib Proteasome Inhibitor Injection